Business Context and Reporting Period
Company: Exagen Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 23, 2021
Event: Entry into a Material Definitive Agreement (Sub-Lease) and creation of a direct financial obligation.
Key Financial Metrics and Obligations
This filing does not report revenue, profit, cash flow, margins, or general liquidity metrics. It discloses specific lease-related financial commitments:
- Security Deposit: $153,073 payable to Plum Healthcare Group, LLC.
- Monthly Base Rent: $66,021 commencing October 1, 2021.
- Rent Escalation: Approximately 3% annual increase beginning October 1, 2022.
- Lease Term: October 1, 2021, to April 30, 2027.
- Abatement: Base rent abatement applies for a specified period starting November 1, 2021.
Material Changes and Operational Impact
The Company has secured approximately 28,000 square feet of additional office space at 2175 Salk Avenue, Carlsbad, California. This represents a material expansion of physical operations. The agreement is a sub-lease from Plum Healthcare Group, LLC, incorporating terms from the Master Lease with Brookwood CB I, LLC and Brookwood CB II, LLC.
Guidance, Risks, and Contingencies
- Termination Risk: The Company does not have a right to terminate the Sub-Lease or the Master Lease.
- Default Consequences: Upon an event of default, the Master Landlord (Brookwood CB) may terminate the Master Lease, and Plum Healthcare may terminate the Sub-Lease.
- Documentation: The full text of the Sub-Lease is not included in this filing but will be filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2021.
Investor Verification Checklist
- Verify the total cash outflow required for the $153,073 security deposit and initial rent payments.
- Confirm the specific duration and value of the rent abatement period starting November 1, 2021.
- Review the upcoming Form 10-Q (Q3 2021) for the full text of the Sub-Lease to assess default provisions and indemnification details.
- Assess the impact of the fixed 3% annual rent escalation on future operating expenses through 2027.